Comparison between crude Interleukin-2 and recombinant Interleukin-2 in maintaining killing activity of cultured lymphocytes
- 21 Downloads
Peripheral blood lymphocytes, regional lymph node lymphocytes or malignant effusion lymphocytes from cancer patients were incubated with crude IL-2 (cIL-2) for 13 days. These effectors, which frequently expressed IL-2 receptor (IL-2R), proliferated well and possessed augmented killing activity against fresh autologous tumor cells and K562. However, when recombinant IL-2 (rIL-2) was added for the last 4 days of culture instead of cIL-2, IL-2R expression and killing activity against fresh autologous tumor cells decreased significantly (P<0.05). Phenotypic analysis indicated that cIL-2 significantly promoted the expansion of the cytotoxic population (CD8+ .11b−)(P<0.05). The decreases in killing activity and IL-2R expression were restored by 0.004% PHA plus rIL-2, but not in the presence of rIFN-γ, rIL-1α, rIL-lβ, rIL-4 or rIL-6. PHA-free cIL-2 maintained killing activity, but not IL-2R expression.
We conclude that some factors in cIL-2 and a low dose of PHA-P are necessary for the maintenance of killing activity and IL-2R expression of cultured lymphocytes in the late phase of culture.
Key wordscrude Interleukin-2 recombinant Interleukin-2 killing activity IL-2 receptor expression
cytotoxic T lymphocytes
lymphokine activated killer
Unable to display preview. Download preview PDF.
- 2.Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889.PubMedGoogle Scholar
- 6.Kimoto Y, Tanji Y, Fujiwara A, Tanaka T, Taguchi T. 1988. Effect of anti-T3 (CD3) monoclonal antibody OKT3 on the proliferation of LAK cells and cytotoxicity. Biotherapy (Japan) 2 (2): 380.Google Scholar
- 8.Hori T, Kan N, Yamasaki N, Nio Y, Ohgaki K, Tobe T. 1985. The cytotoxic activity of tumor infiltrating lymphocytes (TIL) and its application for adoptive immunotherapy. J Jpn Soc Cancer Ther 20: 943.Google Scholar
- 9.Hori T, Kan N, Nio Y, Tsuchitani T, Inamoto T, Kodama H, Tobe T. 1986. Augmentation by OK-432 of cytotoxic activities of lymphocytes in carcinomatous pleural effusions and its application for adoptive immunotherapy. In new application of OK-432. T. Tobe, eds. Excerpta Medica, Tokyo, Japan, 132.Google Scholar
- 10.Kan N, Ohgaki K, Yamasaki N, Hori T, Nakayama N, Nio Y, Inamoto T, Hikasa Y. 1983b. Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: A clinical trial. Arch Jpn Chir 52: 841.Google Scholar
- 11.Kan N, Ohgaki K, Inamoto T, Kodama H. 1984. Anti-tumor and therapeutic effects of spleen cells from tumorbearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immnother 18: 215.Google Scholar
- 13.Ohno T, Kanoh T, Suzuki T, Masuda T, Kuribayashi K, Araya S, Arai H, Uchino H. 1988. Comparative analysis of lymphocyte phenotype between carrier of human immunodeficiency virus (HIV) and adult patients with primary immunodeficiency using two-color immunofluorescence Flow-cytometry. Tohoku J Exp Med 154: 157.PubMedGoogle Scholar
- 24.Takatsu K, Kikuchi Y, Takahashi T, Honjo T, Matsumoto M, Harada N, Yamaguchi N, Tominaga A. 1987. Interleukin 5, a T-cell-derived B-cell differentiation factor also induced cytotoxic T lymphocyte. Immunol 84: 4234.Google Scholar
- 27.Doyle MV, Lee MT, Fong S. 1985. Comparison of the biological activities of human recombinant interleukin-2125 and native interleukin-2. J Biol Resp Modif 4 (1): 96.Google Scholar
- 29.Matis LA, Shu S, Groves ES, Zinn S, Chou T, Kruisbeek AM, Rosenstein M, Rosenberg SA. 1986. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL-2 receptor expression. J Immunol 136: 3496.PubMedGoogle Scholar